Seaward Management Limited Partnership cut its stake in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 5.9% during the second quarter, Holdings Channel reports. The firm owned 31,800 shares of the company’s stock after selling 2,000 shares during the period. Seaward Management Limited Partnership’s holdings in Anika Therapeutics were worth $1,706,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Renaissance Technologies LLC raised its position in Anika Therapeutics by 165.8% in the first quarter. Renaissance Technologies LLC now owns 300,400 shares of the company’s stock valued at $13,434,000 after buying an additional 187,400 shares during the period. Acadian Asset Management LLC raised its position in Anika Therapeutics by 17.4% in the first quarter. Acadian Asset Management LLC now owns 173,771 shares of the company’s stock valued at $7,771,000 after buying an additional 25,727 shares during the period. Teachers Advisors Inc. raised its position in Anika Therapeutics by 4.9% in the first quarter. Teachers Advisors Inc. now owns 160,397 shares of the company’s stock valued at $7,173,000 after buying an additional 7,500 shares during the period. Bogle Investment Management L P DE raised its position in Anika Therapeutics by 118.1% in the first quarter. Bogle Investment Management L P DE now owns 110,969 shares of the company’s stock valued at $4,962,000 after buying an additional 60,087 shares during the period. Finally, Geode Capital Management LLC raised its position in Anika Therapeutics by 13.7% in the first quarter. Geode Capital Management LLC now owns 108,619 shares of the company’s stock valued at $4,856,000 after buying an additional 13,126 shares during the period. 77.85% of the stock is currently owned by hedge funds and other institutional investors.

Anika Therapeutics Inc. (NASDAQ:ANIK) traded up 0.71% during trading on Wednesday, reaching $47.93. 142,791 shares of the company’s stock traded hands. The stock has a market capitalization of $708.26 million, a P/E ratio of 20.92 and a beta of 1.50. Anika Therapeutics Inc. has a 1-year low of $30.93 and a 1-year high of $54.96. The stock has a 50-day moving average price of $48.18 and a 200 day moving average price of $47.84.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Wednesday, July 27th. The company reported $0.57 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.13. The company had revenue of $26.60 million for the quarter, compared to analyst estimates of $24.75 million. Anika Therapeutics had a net margin of 33.77% and a return on equity of 17.24%. Anika Therapeutics’s revenue for the quarter was up 16.2% on a year-over-year basis. During the same quarter last year, the business earned $0.51 EPS. Equities research analysts expect that Anika Therapeutics Inc. will post $2.00 earnings per share for the current year.

Separately, Zacks Investment Research upgraded shares of Anika Therapeutics from a “hold” rating to a “strong-buy” rating and set a $58.00 price objective for the company in a research note on Monday, August 1st.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.

5 Day Chart for NASDAQ:ANIK

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.